Drug Trial Radar · NCT05570006
Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Mar 16, 2023
Primary completion
Dec 23, 2024
Study completion Dec 23, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Oct 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective ABBV-668 is in treating adult participants with UC. Adverse events and change in disease activity will be assessed. ABBV-668 is an investigational drug being developed for the treatment of moderate to severe UC. Approximately 40 adult participants diagnosed with UC will be enrolled in approximately 30 sites globally. Participants will receive oral capsules of ABBV-668 twice daily for 16 weeks and will undergo a 30 day follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Conditions
- Ulcerative Colitis
Interventions
ABBV-668Drug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Endoscopic ImprovementTime frame: Week 8
- Number of Participants With Adverse Events (AEs)Time frame: From the time of first study drug administration until 30 days after the last dose of study drug (Up to approximately 20 weeks)
Locations
30 sites in 4 countries. Site status is shown where the registry gives one.
Gastro SB /ID# 249271
Chula Vista, California
Ctr for Advanced Gastroenterol /ID# 249226
Maitland, Florida
Atlantic Medical Research /ID# 249213
Margate, Florida
Endoscopic Research, Inc. /ID# 249202
Orlando, Florida
Gastroenterology Associates of Central Georgia, LLC /ID# 249278
Macon, Georgia
NYU Langone Long Island Clinical Research Associates /ID# 250075
Lake Success, New York
Columbia University Medical Center /ID# 250189
New York, New York
Lenox Hill Hospital /ID# 250008
New York, New York
Atrium Health /ID# 249273
Charlotte, North Carolina
Options Health Research, LLC /ID# 249216
Tulsa, Oklahoma
University of Pennsylvania /ID# 250012
Philadelphia, Pennsylvania
Allegheny Singer Research Institute d/b/a AHN Research Institute /ID# 250079
Pittsburgh, Pennsylvania
University of Pittsburgh MC /ID# 250071
Pittsburgh, Pennsylvania
Gastroenterology Associates, P.A. of Greenville /ID# 249217
Greenville, South Carolina
Quality Medical Research /ID# 251125
Nashville, Tennessee
Digestive Health Associates of Texas (DHAT) Research Institute - Garland /ID# 249208
Garland, Texas
Baylor College of Medicine /ID# 249203
Houston, Texas
Southern Star Research Institute, LLC /ID# 249212
San Antonio, Texas
Groupe Sante CHC - Clinique du MontLegia /ID# 248928
Liège, Belgium
UZ Gent /ID# 248605
Ghent, Oost-Vlaanderen, Belgium
Vitaz /Id# 248607
Sint-Niklaas, Oost-Vlaanderen, Belgium
Universitair Ziekenhuis Leuven /ID# 248598
Leuven, Vlaams-Brabant, Belgium
CHU Montpellier - Hopital Saint Eloi /ID# 251876
Montpellier, Herault, France
Centre Medico Chirurgical Ambroise Pare Hartmann /ID# 252357
Neuilly-sur-Seine, Île-de-France Region, France
CHU Grenoble - Hopital Michallon /ID# 252108
La Tronche, Isere, France
Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord /ID# 251875
St-Priest-en-Jarez, Pays de la Loire Region, France
Gastromed Sp. z o.o /ID# 255664
Torun, Kuyavian-Pomeranian Voivodeship, Poland
Medical Network Sp.z.o.o. WIP Warsaw IBD Point Profesor Kierkus /ID# 255663
Warsaw, Masovian Voivodeship, Poland
Endoskopia Sp. z o.o. /ID# 255667
Sopot, Pomeranian Voivodeship, Poland
H-T Centrum Medyczne Endoterapia /ID# 255666
Tychy, Silesian Voivodeship, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.